Study to Evaluate Serum Homocysteine Levels as Marker of Peripheral Arterial Disease in a Tertiary Care Hospital in India
Main Article Content
Abstract
Background: The study is aimed to evaluate the association between raised serum Homocysteine levels and severity of Peripheral Vascular Disease (PVD) and its role as a prognostic marker in PVD. Thereby, Vitamin K therapy can be instituted for lowering Homocysteine levels as prophylaxis against cerebral and coronary events in PVD patients.
Methods: The serum homocysteine levels was measured in all patients admitted for peripheral vascular disease of upper and/or lower limb and to correlate the abovevalues with Doppler ultrasonography (USG) in the duration between 2020-2022(18 months)
Results: The comparison of homocysteine levels with Doppler shows corresponding significant increase in Serum homocysteine levels only in cases of moderate PVD. Statistical analysis with binary logistic regression does show a significant association with moderate severity of PVD and serum homocysteine levels with 80% predictability.
Conclusions: There was significant association of homocysteinemia only in Moderate PVD with no statistically significant correlation with mild, severe cases of peripheral arterial disease (PAD) and radiological normal cases, further large randomized trials are required to elucidate its clinical relevance in PAD as a prognostic marker of Severity.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am CollCardiol. 2006;47:1239-312.
II. Dehmer GJ, Badhwar V, Bermudez EA, Cleveland Jr JC, Cohen MG, D’Agostino RS, Ferguson Jr TB, Hendel RC, Isler ML, Jacobs JP, Jneid H. 2020 AHA/ACC key data elements and definitions for coronary revascularization: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop clinical data standards for coronary revascularization). Journal of the American College of Cardiology. 2020 Apr 28;75(16):1975-2088.
III. Khan TH, Farooqui FA, Niazi K. Critical Review of the Ankle Brachial Index. CurrCardiol Rev. 2008 May;4(2):101–6.
IV. Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arteriosclerosis, thrombosis, and vascular biology. 2009 Jul 1;29(7):983-91.
V. Alahdab F, Wang AT, Elraiyah TA, Malgor RD, Rizvi AZ, Lane MA, Prokop LJ, Montori VM, Conte MS, Murad MH. A systematic review for the screening for peripheral arterial disease in asymptomatic patients. Journal of vascular surgery. 2015 Mar 1;61(3):42S-53S.
VI. Townsend CM. Sabiston textbook of surgery E-Book: the biological basis of modern surgical practice. Elsevier Health Sciences; 2021 Jan 8.
VII. Chahal S, Vohra K, Syngle A. Association of sudomotor function with peripheral artery disease in type 2 diabetes. Neurological Sciences. 2017 Jan;38(1):151-6.
VIII. Babatunde AI. Medical Management of Peripheral Artery Disease in Patient with Diabetic Foot Ulcer: A Case Report. Intern Med. 2000;160(19):2934-8.
IX. Yang CP, Lin CC, Li CI, Liu CS, Lin CH, Hwang KL, Yang SY, Li TC. Fasting plasma glucose variability and HbA1c are associated with peripheral artery disease risk in type 2 diabetes. Cardiovascular diabetology. 2020 Dec;19(1):1-3.
X. Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a metaanalysis. JAMA.2008; 300:197-208.
XI. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) Lancet. 1996;348:1329-39.
XII. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-6.
XIII. Heald CL, Fowkes FG, Murray GD, Price JF, Ankle Brachial Index Collaboration. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atheroscl. 2006;189(1):61-9.
XIV. Pasternak RC, Criqui MH, Benjamin EJ, Fowkes FG, Isselbacher EM, McCullough PA, et al. Atherosclerotic vascular disease conference: writing group I: epidemiology. Circulation. 2004;109(21):2605-12.
XV. Suurkula M, Fagerberg B, Wendelhag I, Agewall S, Wikstrand J. Atherosclerotic disease in the femoral artery in hypertensive patients at high cardiovascular risk. The value of ultrasonographic assessment of intima-media thickness and plaque occurrence. Risk Intervention Study (RIS) Group. ArteriosclerThrombVasc Biol. 1996;16:971-7.
XVI. Arnlov J, Pencina MJ, Amin S, Nam BH, Benjamin EJ, Murabito JM, et al. Endogenous sex hormones and cardiovascular disease incidence in men. Ann Intern Med. 2006;145: 176-84.
XVII. Anderson PL, Gelijns A, Moskowitz A, Arons R, Gupta L, Weinberg A, et al. Understanding trends in inpatient surgical volume: vascular interventions, 1980-2000. J Vasc Surg. 2004;39(6):1200-8.
XVIII. Athyros VG, Mikhailidis DP, Papageorgiou AA,Didangelos TP, Ganotakis ES, Symeonidis AN, et al. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Current Med Resea Opinion. 2004;20(11):1691-701.